

Exacerbation of erythropoietic protoporphyria by hyperthyroidism

Elisabeth I. Minder · Andreas R. Haldemann ·
Xiaoye Schneider-Yin

Received: 7 July 2010 / Revised: 6 October 2010 / Accepted: 14 October 2010 / Published online: 11 November 2010
© SSIEM and Springer 2010

Abstract Erythropoietic protoporphyria (EPP) is a hereditary disorder caused by deficiency of ferrochelatase, the last enzyme in the heme biosynthetic pathway. The majority of EPP patients present with a clinical symptom of painful phototoxicity. Liver damage, the most serious complication of EPP, occurs in <5% of the patients. This report describes a case of an EPP patient who complained of worsening cutaneous symptoms, nervousness, and insomnia. Laboratory tests showed highly increased protoporphyrin concentration in erythrocytes and elevated serum transaminases that are indicative of EPP-related liver damage. The subsequent finding of decreased serum thyroid-stimulating hormone (TSH) and increased free triiodothyronine (FT3) and free thyroxine (FT4) concentrations, as well antibodies against both thyroid peroxidase (TPO) and TSH receptors, led to the diagnosis of Graves' disease. The patient received 500 MBq of radioiodine (I^{131}). Three months after the radioactive iodine therapy, the thyroid volume was reduced to 30% of pretherapeutic volume. Although the patient was slightly hypothyroidic, his liver enzymes returned to normal, his erythrocytic protoporphyrin concentration dropped fivefold, and his skin symptoms improved dramatically. The coexistence of Graves' disease and EPP is a statistically rare event as, besides our patient, there was one additional case reported in the literature. Although the exact mechanism

whereby Graves' disease interacts with EPP is yet to be explored, we recommend testing thyroid function in EPP patients with liver complication to exclude hyperthyroidism as a potential cause.

Abbreviations

EPP	Erythropoietic protoporphyria
XLDPP	X-linked dominant protoporphyria
FECH	Ferrochelatase
ALAT	Alanine aminotransferase
ASAT	Aspartate aminotransferase
ULN	Upper limit of normal
RDW	Red cell distribution width
MCV	Mean corpuscular volume
MCH	Mean corpuscular hemoglobin
TSH	Thyroid stimulating hormone
TPO	Thyroperoxidase
FT3	Free triiodothyronine
FT4	Free thyroxine
PAS	Periodic acid-Schiff

Introduction

Erythropoietic protoporphyria (EPP) is a rare inherited disease of heme biosynthesis. The affected enzyme, ferrochelatase, is the ultimate enzyme of the heme biosynthetic pathway and catalyses the insertion of iron into protoporphyrin to form heme (Anderson et al. 2001). A clinically similar disease, X-linked dominant protoporphyria (XLDPP), is caused by activating mutations of aminolevulinic synthase 2, the first enzyme of the pathway (Whatley et al. 2008). In both disorders, accumulation of the substrate of

Communicated by: Ertan Mayatepek

Competing interests: None declared.

E. I. Minder (✉) · X. Schneider-Yin
Central laboratory, Triemli Hospital,
Zurich, Switzerland
e-mail: elisabeth.minder@triemli.stzh.ch

A. R. Haldemann
Institute for Nuclear Medicine, Triemli Hospital,
Zurich, Switzerland

ferrochelatase, protoporphyrin IX, leads to dermal phototoxicity, which mainly affects the face and back of the hands. Seven years after the first description of EPP by Magnus et al. in 1961, Barnes et al. (1968) reported a case of EPP-related terminal liver failure elicited by hepatic accumulation of protoporphyrin IX. The life-long risk of terminal liver failure is estimated to be between 1% and 4% (Holme et al 2006; Doss and Frank 1989). A dramatic increase in the erythrocytic protoporphyrin concentration, together with a decrease of fecal protoporphyrin elimination and an increase in the amount of urinary coproporphyrin I-isomer, is regarded as a sign of impending EPP liver disease (Gross et al. 1998). Alcohol overconsumption was the first identified risk factor for the development of EPP-related liver failure (Bonkovsky and Schned 1986). Later, genetic factors, including null-allele mutations in the ferrochelatase (*FECH*) gene, as well as hypermethylation of the nonmutated *FECH* allele, were added (Minder et al 2002; Onaga et al 2004). Limited data available so far indicates that patients with the variant *XLDPP* are at a higher risk of developing liver affection than those with the classic EPP.

We report here that hyperthyroidism, a treatable disease, caused exacerbation of the cutaneous symptoms, a massive increase in the level of erythrocytic protoporphyrin concentration, and signs of liver involvement in a patient with classic EPP.

Case report

The 40-year-old man complained of worsening skin phototoxicity during the previous 6 months when he visited our clinic in early 2006. He presented with the typical EPP skin lesion on the nose. In addition, he also suffered from anxiety and insomnia. The patient was severely affected by phototoxicity during early childhood. As an adult, he had learned to cope with the disease and was able to carry out his daily activities without much restraint until late 2005. The diagnosis of EPP was made 13 years earlier at the French Center for Porphyrrias, Paris, France, on the basis of reduced ferrochelatase activity in peripheral blood mononuclear cells. No record was available on the blood protoporphyrin concentration at the time of diagnosis. However, his urinary porphyrin concentrations were reportedly normal. Skin histology at that time showed abnormalities typical for EPP, including periodic acid-Schiff (PAS) deposits around the capillaries. The erythrocytic protoporphyrin concentration at his initial visit to our clinic was increased to a level that we considered as potentially risky for developing EPP liver affection, i.e., >40 $\mu\text{mol/L}$ red blood cell (RBC) count. Liver function was therefore evaluated. As shown in Table 1, serum alanine aminotransferase (ALAT) was nearly two times above the upper limit of normal (ULN), and serum

aspartate aminotransferase (ASAT) was slight above the ULN. The patient reported no excess alcohol consumption.

The patient's *FECH* gene was subsequently sequenced, leading to the identification of a heterozygous mutation, *p.* W34X. This is a known mutation of the *FECH* gene first described by Gouya et al. (2004). The patient was also heterozygous for the intronic polymorphism IVS3-48c/t. This genetic constellation confirmed the diagnosis of classic EPP. Hematologic values were largely normal, except for a slight increase in the RBC distribution width (RDW) and decreases in mean corpuscular volume (MCV) and mean corpuscular hemoglobin (MCH), a frequent finding among EPP patients (Holme et al. 2007; Delaby et al. 2009; Wahlin 2010). At the patient's second visit to our clinic 3 months later, both his protoporphyrin concentration and liver enzyme values remained unchanged. However, the concentration of urinary porphyrins, in particular coproporphyrin isomer I, was increased, which was a sign of cholestasis.

Because of his complains of nervousness and insomnia, thyroid function tests were performed. The results showed a decrease in serum TSH and a concomitant increase of both FT3 and FT4 (Table 1). In addition, antibodies against both thyroperoxidase (TPO) and TSH receptor (TRAb) were detected. Radioiodine uptake was increased, and the uptake was diffusely distributed over the entire gland, as demonstrated by scintigraphy. (Table 1). A diagnosis of Graves' disease was therefore made. Radioactive iodine therapy was chosen over thyrostatic drugs taking into consideration that these drugs, as an adverse effect, may cause further damage to the patient's liver. He received 500 MBq of I^{131} , corresponding to an ablative thyroid dose of 200 Gy. Six weeks later, mild hypothyroidism developed. He was substituted with thyroxine. Three months after the radioactive iodine therapy, the patient remained slightly hypothyroidic, and the dosage of thyroxine was therefore increased. Also, his thyroid volume, as determined by sonography, was decreased to 30% of the pretherapeutic volume (8 vs. 27 ml; Table 1). At the same time, a fivefold drop in the concentration of erythrocytic protoporphyrin was measured. Concomitantly, urinary porphyrin concentration and liver enzymes all returned to normal. Meanwhile, the patient noticed a dramatic improvement in his skin condition, i.e., the cutaneous phototoxicity was reduced to the degree he was accustomed to.

Discussion

Graves' disease is a relatively common disorder that occurs at any age but is especially common in the third and fourth decades of life. It can be found in approximately 1% of the population, or 1:89 individuals (Hollowell et al. 2002).

Table 1 Laboratory analyses of the Swiss and the Japanese patients

	The Swiss patient						The Japanese patient								
	Before treatment			After treatment			Before treatment		After treatment						
	Date	Value	Reference	Date	Value	Reference	Date	Value	Reference						
Free protoporphyrin in EC	28 Mar 2006	55.20 (<0.2 µmol/L)		07 June 2006	48.9		05 July 2006	17 July 2006	07 Aug 2006	09 Nov 2006	25 Oct 1969	10 Nov 1969	11 Dec 1969	27 Jan 1970	20 Mar 1970
Fecal protoporphyrin															
Urinary coproporphyrin I ^a					16.0 (<8.4)										
Urinary coproporphyrin III ^a					10.9 (<17.8)										
Ferrochelatase activity (units)		1.2 (5±1.5)													
Ferrochelatase genotype		p.W34X, IVS3-48c/t													
TSH (0.3-5.0)					0.01			< 0.01		0.07					
FT3 (3.1-7.2)					17.2			28.8		1.6					
FT4 (11-26)					40			50.9		5.6					
TRAb (<1)								8.6							
RAIU								24 h:75.6%; 48 h: 63.6%							
Thyroid volume (<25 ml)								27							
ASAT		40 (<37)							42						
ALAT		75 (<41)							88						
Alkaline phosphatase		69 (<117)							82						
Red blood cells (mio/ul)															
Hemoglobin (g/dl)															
Erythrocyte half life					14.1										

Pathological values are in **bold**

EC erythrocyte, FT3 Free triiodothyronine, FT4 free thyroxine, TRAb thyroid-stimulating hormone receptor antibody, RAIU thyroid radioactive iodine uptake, ASAT aspartate aminotransferase, ALT alanine aminotransferase, PBI protein-bound iodine, RDW red blood cell distribution width, KAU neg king armstrong unit negative

^a nmol/mmol creatinine

However, the chance for coexistence of Graves' disease and EPP is very low, i.e., 1:13 million individuals, since EPP is a relatively rare inborn disorder with an estimated prevalence of about 1:150,000 individuals (Schneider-Yin et al. 2009). The scarcity is evidenced by the fact that so far, only one additional case of EPP combined with Graves' disease has been reported in the literature, which was in 1969 (Yamada et al. 1971). In that report, the 16-year-old Japanese patient presented with a clinical course very similar to that of our patient, i.e., aggravation of EPP symptoms and signs of protoporphyria-induced liver disease at the time when Graves' disease was diagnosed. The symptoms included dark skin rashes, signs of hyperthyroidism, jaundice, abnormal liver function, and a massive increase in erythrocytic protoporphyria concentration (Table 1). As in our patient, the conditions in the Japanese patient improved dramatically after successful treatment of hyperthyroidism, i.e., normal liver function was restored and erythrocytic protoporphyria concentration diminished (Yamada et al. 1971). The occurrence of Graves' disease in EPP, although very rare, caused an exacerbation of skin symptoms and more importantly, deterioration in liver function, in both patients, so that they were at risk of developing liver disease, the most serious and potentially life-threatening complication of EPP.

Interaction between hyperthyroidism and EPP is theoretically possible, as both diseases affect the liver and bone marrow. In EPP, bone marrow is the main source of protoporphyria overproduction during erythropoiesis, whereas the liver/biliary tract is the only excretory route for excess protoporphyria due to its hydrophobic nature. EPP patients present frequently with normo- to microcytic anemia due to disturbance in iron metabolism or iron distribution in the body (Lyouni et al 2007; Holme et al 2007) or to a decreased rate of heme synthesis as the result of deficient ferrochelatase activity.

Mild liver dysfunction featured by elevated liver enzymes occurs frequently in hyperthyroid patients, whereas icterus can be observed in severe thyrotoxicosis (Gurlek et al. 1997; Beaver and Pemberton 1933). Erythropoiesis on the other hand, is increased in hyperthyroidism in order to meet the demand of an increase in oxygen delivery to the peripheral tissues. The enhanced erythropoiesis is reflected by a hypercellular bone marrow, in particular, an increased number of erythrocyte precursors. In general, hyperthyroid patients show increases in both the total RBC mass and total blood volume. As a result, their hemoglobin concentration could remain normal. Additional signs of enhanced erythropoiesis, including increased hemoglobin synthesis, shortened plasma iron clearance time, and increased iron turnover and RBC radioiron incorporation, can be observed in some hyperthyroid patients (18). In other patients, how-

ever, there is evidence of ineffective erythropoiesis, as seen by reduced MCV and erythrocyte survival time (Ford and Carter 1988). Iron deficiency, which negatively affects erythropoiesis, is also frequently observed in hyperthyroidism.

Experimental evidence, which indicate a possible link between thyroid hormone and the heme biosynthesis, came from a study of Bauer et al. (1998). In that study, the thyroid hormone receptor α (c-ErbA/TR α) was shown to be involved in the terminal differentiation of erythroid progenitors, i.e., upon binding to its ligand T3, c-ErbA/TR α induced a switching from proliferation to differentiation in gc-ErbA erythroblasts. Among the enzymes involved in erythroid differentiation, aminolevulinic acid synthase (ALAS) is the initial and rate-limiting enzyme of heme biosynthesis. In a study by Zenke et al. (1990), the amount of ALAS transcript in v2-ErbA-expressing erythroblasts was markedly increased in response to T3.

In both protoporphyrias—EPP and XLDPP—protoporphyria IX accumulates in erythroblasts during the heme biosynthesis as the result of either a deficient ferrochelatase or an overactivity of ALAS-2 (the erythroid-specific ALAS). Based on the available information, it remains unclear whether hyperthyroidism causes exacerbation of EPP by increasing the rate of heme synthesis, by impairing liver excretory function for protoporphyria, or by other unknown mechanisms. Therefore, we recommend testing thyroid function in protoporphyria patients with an accompanying liver malfunction in order to exclude hyperthyroidism as a potential cause.

References

- Anderson K, Sassa S, Bishop D, Desnick R (2001) The porphyrias. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) Childs B, Kinzler KW, Vogelstein B, assoc. eds. The metabolic and molecular basis of inherited disease, 8th edn. New York: McGraw-Hill, 2991-3062
- Barnes HD, Hurworth E, Millar JH (1968) Erythropoietic porphyria hepatitis. *J Clin Pathol* 21:157–159
- Bauer A, Mikulits W, Lagger G, Stengl G, Brosch G, Beug H (1998) The thyroid hormone receptor functions as a ligand-operated developmental switch between proliferation and differentiation of erythroid progenitors. *EMBO J* 17:4291–4303
- Beaver DC, Pemberton JD (1933) The pathologic anatomy of the liver in exophthalmic goiter. *Ann Intern Med* 7:687–708
- Bonkovsky HL, Schned AR (1986) Fatal liver failure in protoporphyria. Synergism between ethanol excess and the genetic defect. *Gastroenterology* 90:191–201
- Delaby C, Lyouni S, Ducamp S, Martin-Schmitt C, Gouya L, Deybach JC, Beaumont C, Puy H (2009) Excessive erythrocyte PPIX influences the hematologic status and iron metabolism in patients with dominant erythropoietic protoporphyria. *Cell Mol Biol (Noisy-le-grand)* 55:45–52
- Doss MO, Frank M (1989) Hepatobiliary implications and complications in protoporphyria, a 20-year study. *Clin Biochem* 22:223–229

- Ford HC, Carter JM (1988) The haematology of hyperthyroidism: abnormalities of erythrocytes, leucocytes, thrombocytes and haemostasis. *Postgrad Med J* 64:735–742
- Gouya L, Puy H, Robreau AM et al (2004) Modulation of penetrance by the wild-type allele in dominantly inherited erythropoietic protoporphyria and acute hepatic porphyrias. *Hum Genet* 114:256–262
- Gross U, Frank M, Doss MO (1998) Hepatic complications of erythropoietic protoporphyria. *Photodermatol Photoimmunol Photomed* 14:52–57
- Gurlek A, Cobankara V, Bayraktar M (1997) Liver tests in hyperthyroidism: effect of antithyroid therapy. *J Clin Gastroenterol* 24:180–183
- Hollowell JG, Staehling NW, Flanders WD et al (2002) Serum TSH, T (4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). *J Clin Endocrinol Metab* 87:489–99
- Holme SA, Anstey AV, Finlay AY, Elder GH, Badminton MN (2006) Erythropoietic protoporphyria in the U.K.: clinical features and effect on quality of life. *Br J Dermatol* 155:574–581
- Holme SA, Worwood M, Anstey AV, Elder GH, Badminton MN (2007) Erythropoiesis and iron metabolism in dominant erythropoietic protoporphyria. *Blood* 110:4108–4110
- Lyoumi S, Abitbol M, Andrieu V et al (2007) Increased plasma transferrin, altered body iron distribution, and microcytic hypochromic anemia in ferrochelatase-deficient mice. *Blood* 109:811–818
- Magnus IA, Jarrett A, Prankerd TA, Rimington C (1961) Erythropoietic protoporphyria. A new porphyria syndrome with solar urticaria due to protoporphyriaemia. *Lancet* 2:448–451
- Minder EI, Gouya L, Schneider-Yin X, Deybach JC (2002) A genotype-phenotype correlation between null-allele mutations in the ferrochelatase gene and liver complication in patients with erythropoietic protoporphyria. *Cell Mol Biol (Noisy-le-grand)* 48:91–96
- Onaga Y, Ido A, Uto H et al (2004) Hypermethylation of the wild-type ferrochelatase allele is closely associated with severe liver complication in a family with erythropoietic protoporphyria. *Biochem Biophys Res Commun* 321:851–858
- Schneider-Yin X, Harms J, Minder EI (2009) Porphyria in Switzerland, 15 years experience. *Swiss Med Wkly* 139:198–206
- Wahlin S (2010) Erythropoietic protoporphyria, clinical and epidemiological aspects. Thesis, Karolinska Institutet (<http://diss.kib.ki.se/2010/978-91-7409-817-4/thesis.pdf>, accessed 20. September 2010).
- Whatley SD, Ducamp S, Gouya L et al (2008) C-terminal deletions in the ALAS2 gene lead to gain of function and cause X-linked dominant protoporphyria without anemia or iron overload. *Am J Hum Genet* 83:408–414
- Yamada K, Nakamura Y, Sekiguchi T, Fueki R, Kobayashi S (1971) Erythropoietic protoporphyria associated with hyperthyroidism and jaundice. *Naika* 28:1171–1174
- Zenke M, Muñoz A, Sap J, Vennström B, Beug H (1990) v-erbA oncogene activation entails the loss of hormone-dependent regulator activity of c-erbA. *Cell* 61:1035–1049